Intellia Therapeutics (NTLA) Research & Development (2016 - 2025)
Historic Research & Development for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $94.7 million.
- Intellia Therapeutics' Research & Development fell 2320.72% to $94.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $417.1 million, marking a year-over-year decrease of 901.56%. This contributed to the annual value of $466.3 million for FY2024, which is 718.09% up from last year.
- According to the latest figures from Q3 2025, Intellia Therapeutics' Research & Development is $94.7 million, which was down 2320.72% from $97.0 million recorded in Q2 2025.
- Intellia Therapeutics' Research & Development's 5-year high stood at $133.1 million during Q1 2022, with a 5-year trough of $39.3 million in Q1 2021.
- Its 5-year average for Research & Development is $97.4 million, with a median of $100.0 million in 2022.
- Its Research & Development has fluctuated over the past 5 years, first soared by 23887.11% in 2022, then plummeted by 2703.26% in 2023.
- Intellia Therapeutics' Research & Development (Quarter) stood at $71.2 million in 2021, then soared by 40.57% to $100.0 million in 2022, then increased by 8.94% to $109.0 million in 2023, then grew by 7.25% to $116.9 million in 2024, then dropped by 18.93% to $94.7 million in 2025.
- Its Research & Development stands at $94.7 million for Q3 2025, versus $97.0 million for Q2 2025 and $108.4 million for Q1 2025.